针对II型粘多糖症的神经学方面:酶替代疗法及其他方面
Alessandra Zanetti1,2, Rosella Tomanin3,4
1Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health SDB, University of Padova, Via Giustiniani, 3, 35128, Padua, Italy.
概括
粘多糖症II型 (MPS II) 是一种罕见的神经代谢疾病. 本综述总结了MPS II的临床方面和中枢神经系统向疗法,包括酶替代疗法 (ERT) 和基因疗法,以应对治疗挑战.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 粘多糖症II型 (MPS II) 是一种罕见的儿科神经代谢疾病,由酸二硫酸酶 (IDS) 缺乏引起.
- 这种缺乏导致糖氨基氨基甘的病态积累,影响多个身体系统并导致渐进的神经功能障碍,特别是在严重的形式.
研究的目的:
- 审查MPS II的临床表现,重点关注神经系统的参与.
- 总结目前和新兴的MPS II治疗策略,重点是针对中枢神经系统 (CNS) 的治疗.
主要方法:
- 对MPS II的临床方面和治疗方法的文献综述.
- 酶替代疗法 (ERT) 疗效和局限性的分析,特别是关于血脑屏障 (BBB) 透.
- 评估各种针对中枢神经系统的策略,包括内ERT,基因疗法 (ex vivo和基于AAV).
主要成果:
- 酶替代疗法 (ERT) 对骨和心脏问题有效性有限,对中枢神经系统损伤无效,原因是无法穿过BBB.
- 最近的ERT增强旨在改善BBB透率.
- 针对中枢神经系统的替代疗法,如内ERT和基因疗法,显示出有希望的结果,但需要进一步评估.
结论:
- MPS II呈现了一系列具有显著神经参与的临床表型,需要有效的中枢神经系统向治疗.
- 虽然ERT有局限性,但持续的进步和基因疗法等替代策略有可能改善MPS II的神经并发症的管理.
更多相关视频
05:55Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
60.6K
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.6K
相关概念视频
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K